Overview:
As per the citing of the National Organization for Rare Diseases (NORD) 2016 report, hepatic encephalopathy is described as brain disorder in patients previously suffering with chronic liver ailments such as liver cirrhosis, hepatitis and acute liver failure. If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering with liver cirrhosis. Hepatic encephalopathy is categorized into 3 types such as Type A (acute liver failure), Type B (portal systemic bypass without liver disease) and Type C (liver cirrhosis). The exact disease etiology is unknown but the disease is triggered by accumulation of toxins in the bloodstream as the diseased liver fails to neutralize the toxins. The clinical manifestation associated with hepatic encephalopathy are confusion, anxiety, lethargy, seizures, confused speech, personality changes and poor body movements. The key factors driving the hepatic encephalopathy therapeutics market are rising prevalence of liver disorders, lack of nutrients in daily food intake and increasing public health awareness resulting in early diagnosis and treatment.
The diagnosis of hepatic encephalopathy includes blood tests, liver function test, detection of serum ammonia levels and an encephalogram of the brain to measure the electrical activity of the brain. There are numerous therapeutic approaches to manage the severity of hepatic encephalopathy, but reduction of plasma ammonia is the most preferred strategy. Lactulose is the first line of treatment as it changes the acidity of the stool in order to reduce the production of ammonia by killing the intestinal bacteria. Probiotics and thiamine are useful in the treatment of hepatic encephalopathy by increasing the expulsion of ammoniagenic bacteria by causing the bowel to get fermented by colonic bacteria to produce lactic and acetic acid. In 2010 the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract producing ammonia.
The hepatic encephalopathy therapeutics market is segmented on the following bases:
- Treatment
- Lactulose
- Rifaximin
- Neomycin
- Probiotics
- Thiamine
- Geography
- North America
- Europe
- United Kingdom
- Germany
- Rest of Europe
- Asia Pacific
- Japan
- China
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
Key players identified for Hepatic Encephalopathy market includes:
ASKA Pharmaceutical Company Ltd., COSMO Pharmaceuticals, Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Lupin, Salix Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc. and other notable players.
This report offers:
- Market assessment is conducted by considering 2017 as the base year, market size and compounded annual growth rate (CAGR) is given for the forecast period from 2018 to 2026
- For the scope of the report attractive investment proposition is given for the geography segments by understanding the prevailing market trends in hepatic encephalopathy therapeutics market
- In the company profiles section product portfolios of different manufacturers are listed. Vital information such as mergers & acquisitions, strategic collaborations and financial health of the key players are also.
